ArticleFrontiers in medicine2025
Isavuconazole in the treatment of acute invasive fungal sinusitis: two case reports and literature review.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paresthesia and Facial Bone Destruction due to Chronic Granulomatous Invasive Aspergillosis in the Left Maxillary Sinus.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Through the analysis of two successfully treated cases of acute invasive fungal rhino-sinusitis (AIFRS) caused by Mucor in our hospital, to enhance the understanding of this disease and explore improved diagnostic and treatment strategies. This study also conducted a comprehensive literature review of AIFRS. This study also provides a comprehensive literature review of Infections of the mucor and aspergillus genera. Methods: The clinical data of two patients with AIFRS admitted to our hospital from 2022 to 2025 were retrospectively analyzed, focusing on risk factors, clinical manifestations, treatment plans, and outcomes. Additionally, we reviewed and analyzed cases of Infections of the Mucor and Aspergillus genera published in PubMed over the past 15 years (2011-2025). Results: A total of 387 cases were included in the analyzed studies. The patient cohort was systematically categorized into two main groups: those with Mucor infection and those with Aspergillus infection. Within the Mucor infection group, four subgroups were further identified. The average age of patients infected with Mucor was 41 ± 31.11 years, while that of patients infected with Aspergillus was 32.5 ± 29.99 years. Since the sample size in some subgroups was less than 5 cases, we chose Fisher's exact test to calculate whether there were significant differences, the efficacy rate of isavuconazole monotherapy (89.47%) was significantly higher than that of amphotericin B monotherapy (59.68%), Conclusion: In the described cases, ours patients received isavuconazole pre- and post-surgery, achieving favorable prognostic outcomes. Literature comparisons further validate these findings, demonstrating that the efficacy of the new triazole drug isavuconazole in treating invasive aspergillosis and mucormycosis significantly surpasses that of amphotericin B, with efficacy comparable to voriconazole (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.